Rundle J S, Scott R
Urology. 1983 Jun;21(6):645-7. doi: 10.1016/0090-4295(83)90216-9.
Previous work has suggested that co-trimoxazole may be superior to trimethoprim in the treatment of complicated urinary tract infection. A prospective study has been done to assess the relative value of the drugs in this situation using trimethoprim at higher than normal dosage. Fifty three patients (33 women and 20 men) were randomly allocated to either a fourteen-day course of co-trimoxazole tabs, 2 twice a day (27 patients) or trimethoprim 250 mg twice a day (26 patients). After patient withdrawals from the study, 17 (77%) of the co-trimoxazole group achieved a sterile urine three weeks after starting treatment compared with 15 (65%) in the trimethoprim group (X2 = 0.80). When those patients with sterile urine at three weeks who could be reassessed four weeks later were analyzed, 8 (89%) of the co-trimoxazole patients maintained a sterile urine against 7 (58%) in the trimethoprim group (X2 = 1.09). Although statistical significance was not attained, the results suggest that even at increased dosage, trimethoprim would not appear to be as efficient as co-trimoxazole in complicated urinary tract infection.
先前的研究表明，复方新诺明在治疗复杂性尿路感染方面可能优于甲氧苄啶。已进行了一项前瞻性研究，以评估在这种情况下使用高于正常剂量的甲氧苄啶时这两种药物的相对价值。53名患者（33名女性和20名男性）被随机分配，分别接受为期14天的复方新诺明片治疗，每日2次，每次2片（27例患者），或甲氧苄啶250毫克，每日2次（26例患者）。在患者退出研究后，复方新诺明组有17例（77%）在开始治疗三周后尿液转为无菌，而甲氧苄啶组为15例（65%）（X2 = 0.80）。对那些在三周时尿液无菌且四周后可重新评估的患者进行分析时，复方新诺明组有8例（89%）维持尿液无菌，而甲氧苄啶组为7例（58%）（X2 = 1.09）。尽管未达到统计学显著性，但结果表明，即使增加剂量，在复杂性尿路感染中，甲氧苄啶的疗效似乎也不如复方新诺明。
